tbuckley/cabot-search huggingface dataset:
A pilot study of myeloablative (MA) autologous stem Cell (Auto SCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children with relapsed/refractory(R/R) Hodgkin’s disease (HD)
Authors: M. Bradley, L. Baldinger, M. Bhatia, J. Garvin, D. George, E. Roman, P. Satwani, P. L. Martin, J. Kurtzberg, M. S. Cairo
Journal: Journal of Clinical Oncology (2007)

20007 Background: Allo SCT may benefit patients with R/R HD by providing a graft vs lymphoma effect. Peggs et al (Lancet 2005) demonstrated durable engraftment and reduced non relapse mortality (NRM) in HD pts post RI Allo SCT. Carella et al (JCO2000) and Gutman et al (BMT2005) demonstrated the success of MA Auto SCT followed by RI AlloSCT in adults with refractory lymphoma. We investigated the feasibility of MA Auto SCT followed by RI Allo SCT in children with R/R HD. Methods: MA conditioning prior to AutoSCT was CTX 1,500 mg/m 2 x 4 d, BCNU 100 mg/m 2 x 3d, VP-16 800 mg/m 2 x 3d. AlloSCT conditioning was fludarabine 30 mg/m 2 x 5d, busulfan 3.2 mg/kg x 2d, and R ATG 2 mg/kg x 4d (unrel. donor). CD20+ patients received rituximab (375 mg/m 2 /wk x4) and all pts received involved field radiotherapy (IFRT). Results: Ten pts have enrolled, 2 pts did not proceed (parental withdrawal) to RI AlloSCT (Donors: 1 MRD, 2 MUD, 5 UCB). Median time to RI AlloSCT after MA Auto SCT was 142 d (97–219). The median cell dose was 3.43 x 10 7 TNC/kg for UCB grafts (n=5). Engraftment was achieved at a median of 20.5 d for PMN and 46.5 d for PLT. Donor chimerism reached ≥ 95% in all pts by day 100 with a median follow up of 703d (128–2025). Toxicities were grade (3) hematuria (n=1), (3–4) infection (n=7), (4) pulmonary fibrosis (n=1), (4) hearing loss (n=1), (4) neurotoxicity (n=1). GVHD: grade II-III aGVHD (3/8), cGVHD (3/8). Six patients are alive and NED post allo SCT. There has been one NRM (cGVHD) and one relapse mortality. The OS at one year is 66.7%. Conclusions: MA AutoSCT followed by RI AlloSCT is feasible and well tolerated in pediatric pts with R/R HD. A larger study with longer follow up is required to determine if this approach will reduce relapse, long term toxicity and/or improve survival. No significant financial relationships to disclose.
Persistence of radiation (RT)-induced cardiac perfusion defects 3–5 years post RT
Authors: X. Yu, S. Zhou, D. Kahn, D. R. Hollis, R. G. Prosnitz, P. H. Hardenbergh, M. A. Blazing, T. Wong, S. Borges-Neto, L. B. Marks
Journal: Journal of Clinical Oncology (2004)

625 Background: Tangential photon radiation treatment to the left breast/chest wall has been linked with cardiac dysfunction. In a prospective trial, we have demonstrated that new perfusion defects occurred 6–24 months post-RT (IJROBP 2003;57:S129) in ≈ 40% of patients. We herein assess if these perfusion defects persist with longer follow-up. Methods: Between 1998–2003, 130 patients with left-sided breast cancer were enrolled onto an IRB-approved prospective study to assess RT-induced cardiac dysfunction. All patients received tangent photons to 46–50 Gy, 1.8–2Gy/Fx. Patients had pre- and serial post-RT single photon emission computed tomography (SPECT) scans to assess changes in regional cardiac perfusion. SPECT images were acquired 30–60 min after I.V. administration of 25–30 mCi Tc-99m labeled myocardial perfusion tracer. Patients with pre-RT abnormal perfusion were excluded from this analysis. Twenty-five patients with follow-up scans beyond 2 years form the basis of this report. The incidence of new/persistent perfusion defects beyond 2-years is reported. Results: 16, 7 and 2 patients are evaluable 36-, 48-, and 60-months post-RT, respectively. These 25 patients are divided into 3 subgroups based on their 6–24 month post-RT scans. In those patients whose 6–24 month post-RT scans were consistently abnormal, 6/7 (86%) had persistent abnormalities 3–4 years post-RT. In patients whose 6–24 months post-RT scans were intermittently abnormal (i.e. some scans normal, others abnormal), 5/10 (50%) had abnormal scans 3–5 years post RT. In patients whose scans 6–24 months post-RT were all normal, 4/8 (50%) had abnormal scans 3–5 years post RT. Conclusions: RT-induced perfusion defects can persist 3–5 years post-RT. Somewhat concerning is the observation that new perfusion defects may present 3–4 years post-RT. The clinical relevance of these perfusion defects remains unclear. However, it is possible that such RT-induced perfusion defects represent subclinical microvascular injury, which may render the patients at increased risk for ischemic heart disease. Additional follow-up and study is required. Supported by Grant DAMD 17–98-1–8071 and BC010663 awarded by DOD. No significant financial relationships to disclose.
Diagnostic Accuracy of a Fecal Immunochemical Tests Vary With Neoplasia Location, but not Number of Specimens Analyzed
Authors: Martin C.S. Wong, Jessica Y.L. Ching, Victor C.W. Chan, Siew C. Ng, Sunny H. Wong, Jeffrey P. Shum, Thomas Y.T. Lam, Arthur K.C. Luk, Simon S.M. Ng, Justin C.Y. Wu, Francis K.L. Chan, Joseph J.Y. Sung
Journal: Clinical Gastroenterology and Hepatology (2015)
Notch Signaling In B-ALL Reveals PLK1 As A Potential Therapeutic Target In B-ALL: PLK1-Selective Inhibitor Poloxin Modulates Cyclin B and P53 Pathways, Leading To Growth Arrest and Apoptosis
Authors: Sankaranarayanan Kannan, Mandy A Hall, Leonard S Golfman, Patrick A Zweidler-McKay
Journal: Blood (2013)
<i>TPTE</i> “Cancer/Testis” antigen is a candidate target for immunotherapy in epithelial ovarian carcinoma
Authors: P. K. Singhal, F. Qian, B. Keitz, D. Driscoll, J. Skipper, A. Simpson, L. Old, S. Lele, K. Odunsi
Journal: Journal of Clinical Oncology (2005)

2583 Background: Cancer/testis (CTA) antigens expression is highly tissue-restricted, immunogenic in cancer patients, and are novel targets for cancer vaccine.These CTA are expressed in different tumors and normal testes, but not in other normal tissues. Transmembrane phosphatase with tensin homology (TPTE) is a novel, 2761 bp long CTA located on chromosome 21p11 and shares significant homology with tumor suppressor protein PTEN. Our study goals were to determine TPTE expression in epithelial ovarian carcinoma (EOC) and examine for correlation with clinical outcome. Methods: Frozen specimens were obtained from 100 patients with EOC treated between 1995 and 2003. Following isolation of total RNA, one-step reverse transcriptase PCR (RT-PCR) was performed on the EOC tissues, 8 cancer cell lines (IOSE, HOSE, OVCA-3, OV-2774, SKOV-6, OVCA-429 and SKOV-3) and 16 normal tissues. A 433 bp TPTE specific PCR product was amplified using TPTE specific sense 5’TTTATTCGATTCCTCGTTATGTACG3’ and antisense 5’ACATAATTCTTTCCCAGAAGGG3’ primers. Glyceraldehyde-3-phosphodehydrogenase specific PCR amplification was used a control. The χ2 test and Kaplan-Meier method were used for statistical analysis. Statistical significance was determined by the log-rank test. Results: TPTE was not expressed in any of the normal tissues (including brain, heart, kidney, spleen, lungs) but was expressed in 35 out of 100 (35%) EOC tissues. All cancer cell lines except SKOV-6 expressed TPTE. There were no significant relationships between stage, grade, histology and TPTE +ve and TPTE -ve patients.The median follow up for all patients was 32 months (range 0.5–119 months). Median survival in TPTE negative patients was 40 months (CI:32,48) versus 55 months (CI: 44,66) in TPTE positive patients (not significant). Conclusions: TPTE is expressed in a high proportion of EOC patients. Although there was no significant difference in overall survival in TPTE+ve and TPTE-ve patients, its lack of expression in normal tissues, homology to PTEN and its potential role in tumorigenesis makes TPTE an attractive target for antigen specific immunotherapy for EOC. We are evaluating immunogenicity of TPTE for development of polyvalent CTA vaccine therapy for EOC. No significant financial relationships to disclose.
Soluble Monomeric P-Selectin Containing Only the Lectin and Epidermal Growth Factor Domains Binds to P-Selectin Glycoprotein Ligand-1 on Leukocytes
Authors: Padmaja Mehta, Kamala D. Patel, Thomas M. Laue, Harold P. Erickson, Rodger P. McEver
Journal: Blood (1997)
Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases
Authors: J. Kirkpatrick, A. Desjardins, J. J. Vredenburgh, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, A. H. Friedman, H. S. Friedman, D. A. Reardon
Journal: Journal of Clinical Oncology (2006)

11522 Background: The prognosis for glioblastoma multiforme remains poor. Survival is generally limited to less than 1 year. Currently available standard treatments have not allowed, thus far, to prolong survival significantly. Response rates observed in clinical trials evaluating glioblastoma multiforme are usually less than 20%. Knowing that malignant gliomas have high concentrations of VEGF receptors, and the higher the VEGF receptor concentration, the worse the prognosis, we decided to evaluate the efficacy of bevacizumab in malignant brain tumor patients. Bevacizumab is a humanized IgG1 monoclonal antibody to VEGF, which is synergistic with chemotherapy for most malignancies. We performed a phase II study combining bevacizumab with irinotecan for patient with malignant gliomas and observed an unprecedented response rate of 63%. Methods: Building of those results, we decided to treat a number of our patients with voluminous unresectable disease with bevacizumab and temozolomide as an upfront regimen. Temozolomide is an oral methylating agent known effective for primary malignant brain tumor patients. A phase III trial, first presented at the ASCO meeting of 2003, demonstrated the efficacy of temozolomide for newly diagnosed glioblastoma multiforme patients, establishing temozolomide as the new standard of care. Given the known results with temozolomide as monotherapy and the combination of bevacizumab with irinotecan, we treated patients with temozolomide and bevacizumab upfront. Results: With this new combination, some patients demonstrated dramatic improvement clinically and radiographically. The combination has been well tolerated thus far, with no incidence of hemorrhage or arterial thrombosis observed. Conclusions: Results will be updated at the time of presentation. [Table: see text]
Feasibility study of nipple-sparing mastectomy for Japanese breast cancer patients.
Authors: Maiko Takahashi, Hiromitsu Jinno, Tetsu Hayashida, Yuko Kitagawa
Journal: Journal of Clinical Oncology (2012)

166 Background: Nipple-sparing mastectomy (NSM) has been gathering increased recognition as an alternative to more traditional mastectomy approaches. However, the oncological safety of these procedures is still to be elucidated. The purpose of this study is to investigate technical feasibility of NSM without increasing the risk of local recurrence and complications. Methods: Ninety-eight stage 0-III breast cancer patients received NSM between January 2001 and April 2012 at Keio University Hospital. Eligible patients were without skin involvement and not indicated for breast-conserving therapy by preoperative imaging. The pathological analysis of the subareolar tissue was performed and nipple-areolar-complex (NAC) would be removed if positive. Four hundred seventy-four breast cancer patients who had mastectomy during the same period were used as a control group. Results: The median age was 46.0 years (range 29–68). The mean clinical tumor size was 2.8±1.2cm and the mean distance between the nipple and the tumor was 2.5±1.7cm. Ninety-one patients (92.9%) had clinically node-negative status. NAC involvement was observed in 3 patients (3.1%). Three patients (3.1%) presented with epidermal necrosis. After a median follow-up period of 37.3 months (range 1-136), there were 7 recurrences (7.1%), including 4 local recurrences (4.1%) and 3 distant metastases (3.1%). There was no statistically significant difference in local recurrence between the patients with NSM and mastectomy (4.1% vs. 3.2%; p=0.16). Immediate and delayed reconstruction was performed in 2 cases (2.0%) and 41 cases (41.8%), respectively. Conclusions: Our results suggested NSM may provide oncologic safety for strongly motivated and carefully selected patients.
Safety of transdermal scopolamine in pediatric patients for chemotherapy-induced nausea and vomiting (CINV)
Authors: L. M. Weber, D. Alexander, M. Finkelstein, S. Chen
Journal: Journal of Clinical Oncology (2007)

19568 Background: Transdermal scopolamine has been used for over 25 years in the treatment of nausea and vomiting, but little information is available on its safety in pediatric patients. The antiemetic guidelines established at our hospital allow children between 8 and 15kg to receive a ½ patch every 3 days and children greater than 15 kg to receive 1 patch every 3 days as an adjunct agent for CINV. The goal of this study was to assess the safety of transdermal scopolamine in hospitalized pediatric patients during chemotherapy treatment. Methods: A retrospective chart review was conducted at Children’s Hospital and Clinics of Minnesota from April to September 2005. A total of 82 hospital admissions (41 patients) were reviewed for adverse effects specific to scopolamine using the National Cancer Institute’s Common Terminology Criteria for Adverse Events. Results: Mean patient age was 8 years (1–20 years) and the average length of patch use was 6 days (2–31 days). Of the 82 admissions reviewed, a total of 20 adverse events occurred (24%) in 14 patients. Median weight was significantly greater for patients experiencing the following adverse events compared to patients that did not: headaches (p=0.009), mental status changes (p=0.01) and hallucinations (p=0.003). Age &gt; 12 years (p&lt;0.001) and use of the patch &gt; 4 days (p&lt;0.01) were significantly correlated with the incidence of an adverse event. 75% of patients did not experience an adverse effect from transdermal scopolamine therapy when used 4 days or less. Conclusions: Transdermal scopolamine is a safe adjuvant for treatment of CINV in pediatric patients; however, as many as 1 in 5 may suffer adverse events. When used for more than 4 days the risk of adverse events increases. Older children and adolescents are more prone to adverse events. No significant financial relationships to disclose.
Karyotypic and Surface Features of Murine TA3 Carcinoma Cells During Immunoselection in Mice and Rats&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Hauschka, T. S., Weiss, L., Holdridge, B. A., Cudney, T. L., Zumpft, M., Planinsek, J. A.
Journal: JNCI Journal of the National Cancer Institute (1971)

Journal Article Karyotypic and Surface Features of Murine TA3 Carcinoma Cells During Immunoselection in Mice and Rats Get access T. S. Hauschka, T. S. Hauschka Departments of Biology and Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar L. Weiss, L. Weiss Departments of Biology and Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar B. A. Holdridge, B. A. Holdridge Departments of Biology and Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar T. L. Cudney, T. L. Cudney Departments of Biology and Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Zumpft, M. Zumpft Departments of Biology and Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar J. A. Planinsek J. A. Planinsek Departments of Biology and Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York 14203 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 47, Issue 2, August 1971, Pages 343–359, https://doi.org/10.1093/jnci/47.2.343 Published: 01 August 1971 Article history Received: 28 January 1971 Accepted: 23 April 1971 Published: 01 August 1971
Staging of Breast Cancer: It Is Time to Break With Tradition and Initiate the Evidence-Based-Medicine Age
Authors: Alberto Ravaioli, Davide Tassinari, Ilaria Panzini, Carlo Milandri, Dino Amadori
Journal: Journal of Clinical Oncology (2001)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.4.1234 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11181693 Staging of Breast Cancer: It Is Time to Break With Tradition and Initiate the Evidence-Based-Medicine Age Alberto RavaiolixAlberto RavaioliSearch for articles by this author , Davide TassinarixDavide TassinariSearch for articles by this author , Ilaria PanzinixIlaria PanziniSearch for articles by this author , Carlo MilandrixCarlo MilandriSearch for articles by this author , Dino AmadorixDino AmadoriSearch for articles by this author Show More City Hospital, Rimini, ItalyL. Pierantoni Hospital, Forlì, Italy https://doi.org/10.1200/JCO.2001.19.4.1234 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
THU0583 Emotions Related to Participation Restrictions Experienced by Patients with Early Rheumatoid Arthritis: A Qualitative Interview Study (The Swedish Tira Study)
Authors: G. Ostlund, M. Björk, I. Thyberg, M. Thyberg, E. Waltersson, B. Stenström, A. Sverker
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Psychological distress is a well-known complication in rheumatoid arthritis (RA). It is usually studied by questionnaires with predefined items related to mental functions, and the knowledge regarding the full spectrum of emotions and their relations to practical participation restrictions is still scarce. <h3>Objectives</h3> The aim was to explore emotionsrelated to participation restrictions. <h3>Methods</h3> This study is part of the Swedish TIRA-project [1]. 48 patients with early RA, age 20 – 63, were interviewed about participation restrictions with Critical Incident Technique [2]. Transcribed interviews were synthesized into dilemmas and linked to ICF activity/participation codes [3]. The emotions described by the patients have been condensed and categorized. <h3>Results</h3> Sadness, fear, anger, and shame were expressed in relation to RA participation restrictions. Sadness was described when trying to perform daily activities such as getting up in the mornings, getting dressed, or at work when not being able to perform duties. Sadness was also experienced in relation to not being able to continue leisure activities or in caring for children. Examples of fear descriptions were found in relation to the deteriorating health and fumble fear made the individual withdraw from activities when mistrusting the body. Anger was described in relation to domestic and employed work, but also in social relations when the individual felt hindered to continue valued activities. Shame or embarrassments were described when participation restrictions became visible in public. <h3>Conclusions</h3> Sadness, anger, fear and shame are closely related to practical participation restrictions and may be addressed by corresponding multiprofessional interventions that facilitate participation. <h3>References</h3> Björk, M., Thyberg, I., Rikner, K., Balogh, I., Gerdle, B. (2009). Sick leave before and after diagnosis of rheumatoid arthritis: a report from the Swedish TIRA project. J Rheumatol;36:1170-1179. Flanagan, C. (1954). The critical incident technique. Psychological Bulletin; 51:327-358. Cieza, A., Geyh, S., Chatterji, S., Kostanjsek, N., Ustun, B., Stucki, G. (2005). ICF linking rules; an update based on lessons learned. J Rehabil Med; 37: 212-218. <h3>Disclosure of Interest</h3> None Declared
Scrofula; its Nature, its Causes, its Prevalence, and the Principles of Treatment
Journal: BMJ (1846)

Struma and diseases ascribed to the strumous disposition prevail so extensively, and are so unmanageable, that it is not won- derful to observe that they from time to time give rise to the ap- pearance of various new treatises on the nature, the causes, and the treatment of these disorders.It is indeed true that certain periods seem to be more prolific in the production of these works than others; and though the causes of this occasional profusion of writings on one subject may not at all times be very manifest, yet it is generally possible to trace them to circumstances, the
Effect of Feeding &lt;italic&gt;N&lt;/italic&gt;-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide on Mitotic Activity of Rat Urinary-Bladder Epithelium
Authors: A. J. Tiltman, M.D., G. H. Friedell, M.D.
Journal: JNCI Journal of the National Cancer Institute (1972)

Colchicine metaphase-arrest techniques indicated that, in normal Fischer rats, mitotic activity in the epithelium of the urinary bladder had a circadian rhythm. After N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide was fed to the rats for 4 weeks, this circadian rhythm was no longer found. In addition, the mitotic activity did not differ significantly between the various histologic types of bladder carcinoma produced in rats fed this compound for 25 weeks. The mitotic indices of tumors differed markedly from those of the adjacent nontumorous epithelium.
Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L.
Authors: G V Dahl, G K Rivera, A T Look, H O Hustu, D K Kalwinsky, M Abromowitch, J Mirro, J Ochs, S B Murphy, R K Dodge
Journal: Journal of Clinical Oncology (1987)

Childhood acute lymphoblastic leukemia with an initial leukocyte count greater than or equal to 100 X 10(9)/L responds poorly to conventional chemotherapy. To extend event-free survival (EFS) in this disease, we devised a protocol that specifies intensive 2-week courses of teniposide (VM-26, 165 mg/m2) plus cytarabine (ara-C, 300 mg/m2), before and immediately after standard 4-week remission induction therapy with prednisone, vincristine, and L-asparaginase. The VM-26 and ara-C combination was also administered intermittently for the first year of continuation treatment with oral 6-mercaptopurine and methotrexate. CNS prophylaxis consisted of periodic intrathecal (IT) injections of methotrexate and delayed cranial irradiation. At a median follow-up of 4 years, the estimated EFS rate for 57 consecutive patients with leukocyte counts of 100 to 1,000 X 10(9)/L was 44%, compared with 10% for matched controls (P less than .001). Remission induction rates in the two groups were similar (82% v 72%, P = .16). Twenty-five patients in the VM-26/ara-C group have survived without adverse events for 2.7 to 6.8 years, whereas only nine of the controls achieved more than a year of EFS. The most common complications during early treatment were acute hyperkalemia from rapid tumor cell lysis and infections due to prolonged marrow aplasia. Continuation chemotherapy was well tolerated. We conclude that VM-26 plus ara-C, added to each phase of an otherwise basic regimen of chemotherapy, will substantially improve prognosis in this high-risk form of childhood leukemia.